Autor: |
Wood PM; Department of Pharmacy and Pharmacology and Sterix Ltd. University of Bath, Claverton Down, Bath BA2 7AY, UK., Woo LW, Labrosse JR, Thomas MP, Mahon MF, Chander SK, Purohit A, Reed MJ, Potter BV |
Jazyk: |
angličtina |
Zdroj: |
ChemMedChem [ChemMedChem] 2010 Sep 03; Vol. 5 (9), pp. 1577-93. |
DOI: |
10.1002/cmdc.201000203 |
Abstrakt: |
The design and synthesis of a series of bicyclic ring containing dual aromatase-sulfatase inhibitors (DASIs) based on the aromatase inhibitor (AI) 4-[(4-bromobenzyl)(4H-1,2,4-triazol-4-yl)amino]benzonitrile are reported. Biological evaluation with JEG-3 cells revealed structure-activity relationships. The X-ray crystal structure of sulfamate 23 was determined, and selected compounds were docked into the aromatase and steroid sulfatase (STS) crystal structures. In the sulfamate-containing series, compounds containing a naphthalene ring are both the most potent AI (39, IC(50 AROM)=0.25 nM) and the best STS inhibitor (31, IC(50 STS)=26 nM). The most promising DASI is 39 (IC(50 AROM)=0.25 nM, IC(50 STS)=205 nM), and this was evaluated orally in vivo at 10 mg kg(-1), showing potent inhibition of aromatase (93 %) and STS (93 %) after 3 h. Potent aromatase and STS inhibition can thus be achieved with a DASI containing a bicyclic ring system; development of such a DASI could provide an attractive new option for the treatment of hormone-dependent breast cancer. |
Databáze: |
MEDLINE |
Externí odkaz: |
|